Lido Advisors LLC Has $2.04 Million Stake in Zoetis Inc. $ZTS

Lido Advisors LLC trimmed its stake in Zoetis Inc. (NYSE:ZTS) by 42.4% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 17,207 shares of the company’s stock after selling 12,664 shares during the period. Lido Advisors LLC’s holdings in Zoetis were worth $2,035,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of ZTS. Louisiana State Employees Retirement System bought a new position in Zoetis in the first quarter valued at approximately $2,542,000. Deutsche Bank AG increased its stake in Zoetis by 19.1% in the fourth quarter. Deutsche Bank AG now owns 5,558,183 shares of the company’s stock valued at $699,331,000 after purchasing an additional 891,921 shares in the last quarter. Pincus Capital Management LP bought a new stake in Zoetis in the fourth quarter valued at approximately $2,109,000. Highbridge Capital Management LLC acquired a new stake in Zoetis in the fourth quarter worth $7,004,000. Finally, AE Wealth Management LLC boosted its position in shares of Zoetis by 71.3% during the fourth quarter. AE Wealth Management LLC now owns 144,531 shares of the company’s stock worth $18,185,000 after purchasing an additional 60,167 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis News Roundup

Here are the key news stories impacting Zoetis this week:

• Negative Sentiment: Several firms announced or promoted securities-fraud litigation against Zoetis, which can weigh on sentiment by raising legal, financial, and reputational risk for the company. Zoetis Inc. (ZTS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
• Negative Sentiment: The class-action deadline reminders may keep the controversy in the spotlight and encourage more shareholder claims, adding overhang to the stock. ZOETIS CLASS ACTION DEADLINE MONDAY JULY 27th
• Neutral Sentiment: One Seeking Alpha commentary argues Zoetis sentiment remains strong and fundamentals are improving, offering a more constructive longer-term view. Zoetis: Sentiment Keeps Winning As Fundamentals Improve

Zoetis Price Performance

Shares of NYSE ZTS opened at $75.32 on Monday. The firm has a market cap of $31.58 billion, a PE ratio of 12.49, a PEG ratio of 1.18 and a beta of 0.75. The company has a current ratio of 3.15, a quick ratio of 1.91 and a debt-to-equity ratio of 2.80. Zoetis Inc. has a 1-year low of $71.47 and a 1-year high of $160.48. The company has a fifty day moving average price of $77.29 and a 200 day moving average price of $104.08.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). The firm had revenue of $2.26 billion for the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a return on equity of 66.85% and a net margin of 27.80%.Zoetis’s revenue for the quarter was up 2.9% on a year-over-year basis. During the same quarter last year, the company posted $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Research analysts predict that Zoetis Inc. will post 6.87 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be given a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s dividend payout ratio (DPR) is currently 35.16%.

Insider Activity at Zoetis

In other news, Director Michael B. Mccallister bought 3,000 shares of the business’s stock in a transaction on Monday, May 11th. The shares were purchased at an average price of $77.76 per share, for a total transaction of $233,280.00. Following the purchase, the director owned 24,524 shares of the company’s stock, valued at approximately $1,906,986.24. The trade was a 13.94% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Paul Bisaro purchased 2,000 shares of the firm’s stock in a transaction dated Wednesday, May 13th. The shares were acquired at an average cost of $75.88 per share, with a total value of $151,760.00. Following the completion of the purchase, the director directly owned 27,862 shares in the company, valued at approximately $2,114,168.56. This represents a 7.73% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last quarter, insiders have bought 11,650 shares of company stock valued at $886,384. 0.22% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the stock. Weiss Ratings cut shares of Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, June 12th. Wall Street Zen lowered Zoetis from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. Argus reissued a “hold” rating on shares of Zoetis in a research note on Wednesday, May 27th. Citigroup lowered their price target on Zoetis from $145.00 to $112.00 and set a “buy” rating for the company in a report on Monday, May 18th. Finally, JPMorgan Chase & Co. dropped their price target on Zoetis from $190.00 to $130.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. Eight investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Zoetis presently has an average rating of “Hold” and an average target price of $119.50.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.